MetaCap

Telix Pharmaceuticals (TLX) vs Xeris Biopharma (XERS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Xeris Biopharma (XERS) has outperformed Telix Pharmaceuticals (TLX) over the past year, gaining 148.5% versus a loss of 6.1%. Xeris Biopharma is the larger company by market cap ($3.10 billion vs $2.84 billion), about 1.1 times the size, while Telix Pharmaceuticals is growing revenue faster (+55.6% vs +43.7%). Xeris Biopharma converts more of its revenue into profit, with a net margin of 0.2% versus -0.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

TLX-6.06%XERS+148.46%
+158%+60%-37%
Nov 21, 20251 yearNov 20, 2026
TLX-43.64%XERS+481.16%
+508%+213%-83%
Nov 11, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

TLX versus XERS key metrics
MetricTLXXERS
Share price$8.37$16.97
Market cap$2.84B$3.10B
1-day change-3.90%+2.11%
YTD return+11.75%+116.18%
1-year return-6.06%+148.46%
5-year return—+682.03%
P/E ratio (TTM)83.70—
Forward P/E—63.64
EPS (TTM)$0.10$-0.03
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$803.79M$291.85M
Revenue growth (YoY)+55.61%+43.72%
Net income (latest FY)$-7.13M$554.00K
Gross margin53.05%85.41%
Operating margin3.70%8.53%
Net margin-0.89%0.19%
52-week high$13.11$17.28
52-week low$6.28$5.25
Distance from 52-week high-36.16%-1.79%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+134.89%+1.89%
Average volume356.74K2.86M
Shares outstanding339.78M182.70M
Employees1,120435
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • XERS has outperformed TLX by 154.5 percentage points over the past year.
  • Telix Pharmaceuticals grew revenue faster in its latest fiscal year (+55.61% vs +43.72%).

About Telix Pharmaceuticals

TLX stock →

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,120 employees

About Xeris Biopharma

XERS stock →

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees

TLX vs XERS FAQ

Which is bigger, Telix Pharmaceuticals or Xeris Biopharma?

Xeris Biopharma (XERS) is larger, with a market capitalization of $3.10B compared with $2.84B for Telix Pharmaceuticals (TLX).

Which stock has performed better over the past year, TLX or XERS?

XERS returned +148.46% over the past 12 months, compared with -6.06% for TLX (price return, excluding dividends). Past performance does not predict future results.

Are Telix Pharmaceuticals and Xeris Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons